NCT04539106View on ClinicalTrials.gov

Intravitreal Ranibizumab in Recurrent ROP

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions
Retinopathy of Prematurity
Interventions
DRUG

intravitreal injection of Ranibizumab

intravitreal injection of 0.25 mg/0.025 ml ranibizumab with a 30-gauge needle 1.5mm from limbus

Trial Locations (1)

Unknown

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Ameera Gamal Abdelhameed

OTHER

NCT04539106 - Intravitreal Ranibizumab in Recurrent ROP | Biotech Hunter | Biotech Hunter